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Abstract
Immunoassays are widely used to perform an initial toxicological 
screening of biological samples. However, LC-MS/MS is described 
as a promising technique that can overcome the limitations of 
immunoassays (such as their lack of selectivity). The objective of 
this project was to implement a LC-MS/MS method for screening 
of forensic ante- and post-mortem urine and whole blood samples 
that can replace the immunoassays. Easy and rapid sample 
preparation techniqueswere evaluated. Protein precipitation with 
acetonitrile combined with aqueous dilution (dilution factor 5 for 
urine and 10 for blood) proved to be an effective procedure. On the 
LC-MS/MS, 1 scheduled multiple reaction monitoring transition for 
each of 414 compounds was analyzed in positive mode, followed 
by an enhanced product ion scan if the peak height exceeded a 
specified threshold. In negative ionization mode, 38 compounds 
were measured with a scheduled multiple reaction monitoring 
method. For analysis of THC and two metabolites, a separate 
positive multiple reaction monitoring method was used to enhance 
sensitivity. 162 forensic urine samples and 146 blood samples 
were analyzed with both LC-MS/MS and immunoassay screening. 
LC-MS/MS screening was superior and can be considered as a 
trustworthy alternative to immunoassays in forensic toxicology. 
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Introduction
Immunoassays are widely used for screening of biological samples. 
In case of a positive result, an additional selective confirmation 
analysis is performed. Immunoassays are simple and quick, but 
costly. Moreover, immunoassays are not selective: no individualistic 
compound (e.g. diazepam), but only a group (e.g. benzodiazepines) 
is detected. Besides the compounds included in a group, other 
structurally related compounds can result in a false positive test 
because of cross-reactivity. Not all drug classes are covered by the 
immunoassays and some systems will disappear from the market 
(e.g. Abott Axsym® which is routinely used for screening of forensic 
(i.e. both ante- and post-mortem) urine samples in our laboratory). 
Therefore, we searched for an alternative for the immunoassays for 
screening of forensic urine and whole blood samples.
Two promising approaches using liquid chromatography coupled 
to tandem mass spectrometry (LC-MS/MS) for screening are 
described: multi-target screening and general unknown screening 
[1-6]. In the first approach only a selected group of compounds 
is detected, while this is not limited in the second approach. As a 
consequence, sensitivity of the multi-target screening is in general 
higher, but the number of compounds that can be detected is lower. 
For multi-target screening, a triple quadrupole, ion trap or a hybrid 
instrument combining these two are preferred as the mass analyzer. 
For general unknown screening, measuring the accurate mass of 
compounds using a time-of-flight mass analyzeris becoming more 
and more popular. 
Several simple sample preparation methods for screening with LC-
MS/MS are described [1-6]. For urine, dilution with different dilution 
factors and solvents, protein precipitation with several precipitating 
agents and filtration are used as simple alternatives for more complex 
liquid-liquid extraction (LLE) and solid-phase extraction (SPE) [1-5]. 
Screening of whole blood (especially post-mortem) is more difficult 
than urine or serum/plasma because of the complexity of this matrix. 
This explains why almost all LC-MS/MS methods for screening of 
whole blood use SPE or LLE as sample preparation [1-3]. There is only 
one paper describing a protein precipitation procedure (including an 
evaporation step) for screening of post-mortem whole blood [6]. 
Clearly, research on easy and quick sample preparation for whole 
blood is very limited. Moreover, to the best of our knowledge, there is 
no publication that describes LC-MS/MS screening of both ante- and 
post-mortem urine and whole blood.
The objective of this project was to develop an easy, quick and 
low-cost sample preparation and LC-MS/MS method for screening of 
forensic urine and whole blood samples.
Materials and Methods
Chemicals, standards and samples
CON-DOA®containing known concentrations of amphetamine, 
benzoylecgonine, codeine, dextropropoxyphene, methamphetamine, 
methadone, methaqualone, morphine, oxazepam and phencyclidine 
was purchased from Siemens Medical Solutions Diagnostics 
(LA, USA). The internal standard (IS) N-methylclonazepam was 
purchased from LGC (Molsheim, France). Acetone was purchased 
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from Merck (Darmstadt, Germany). Water was obtained from a 
Milli Q Water Purification System (Millipore, Brussel, Belgium). LC-
MS grade acetonitrile was purchased from Biosolve (Valkenswaard, 
The Netherlands). All LC-MS grade mobile phase additives (formic 
acid and ammonium formate) were purchased from Sigma-
Aldrich (Bornem, Belgium). Glassware was silanized using AquaSil 
Siliconizing Fluid (Thermo Scientific, Breda, The Netherlands). 1.5 mL 
screw cap vials, 100 µL inactivated glass vial inserts, Whatman® Mini-
UniPrep™ syringeless filters with 0.2 µm or 0.45 µm PTFE filtration 
membranes and Toxitubes® were purchased from Agilent (Diegem, 
Belgium). Statistical analyses were performed with GraphPad Prism 
(version 6.01, La Jolla, US).
Immunoassays
For screening of urine samples, a fluorescence polarization 
immunoassay (Abbott Axsym® system, Waver, Belgium) was 
used to detect amphetamine/metamphetamine, barbiturates, 
benzodiazepines, cannabinoids, cocaine and metabolites, methadone, 
opiates and tricyclic antidepressants. Used cutoffs were 50 ng/
mL for cannabinoids and tricyclic antidepressants, 60 ng/mL for 
benzodiazepines, 100 ng/mL for methadone, 150 ng/mL for cocaine, 
200 ng/mL for barbiturates and opiates, 500 ng/mL for (met)
amphetamine. Screening of blood samples was performed with an 
enzyme immunoassay (Cozart® system, Oxfordshire, UK) which 
detected the presence of amphetamine/metamphetamine, barbiturates, 
benzodiazepines, cannabinoids, cocaine and metabolites, methadone 
and opiates. Used cutoffs were 5 ng/mL for methadone, 10 ng/mL for 
cannabinoids, 20 ng/mL for barbiturates, 50 ng/mL for cocaine and 
metabolites, 100 ng/mL for (met)amphetamine, benzodiazepines and 
opiates.
Sample preparation for LC-MS/MS screening
Seven sample preparations were tested for screening of urine 
and blood: (1,2) precipitation with acetonitrile/acetone and aqueous 
dilution; (3,4,5,6) protein precipitation with acetonitrile/acetone, 
aqueous dilution and 0.2/0.45 µm filtration and (7) a simple LLE. For 
the precipitation procedures, 200 µL precipitating solvent (acetonitrile 
or acetone containing 500 ng/mL N-methylclonazepam) was slowly 
dropped to 100 µL supernatant of urine (150 µL urine was centrifuged 
for 10 min, 1000 × g) or blood while vortexing. After centrifugation 
(10 min, 1000 × g) the supernatant was diluted with 700 or 300 µL 
water (equal to a dilution factor 10 or 5) in a 1.5 mL vial or in the 
chamber of a Whatman® Mini-UniPrep™ syringeless filter (in this case 
volumes were decreased by half as the maximum volume of the filter is 
500 µL). The plunger containing the 0.2 µm or 0.45 µm PTFE filtration 
membrane was manually pressed through the diluted sample into the 
chamber and the filtrate is forced into the reservoir of the plunger. The 
Mini-UniPrep filter was then placed in the autosampler of the LC-
MS/MS. Compared to the common use of a syringe and filters, this 
syringeless system reduces waste and avoids contamination. For the 
LLE, the Toxitubes (Toxitubes A for extraction of basic and neutral 
drugs and Toxitubes B for extraction of acidic and neutral drugs) were 
vortexed for 10 s. Next, 100 µL urine or blood, 200 µL IS (500 ng/mL 
N-methylclonazepam in H2O) and 4.7 mL water (in Toxitube A) or 4.2 
mL water (in Toxitube B) were added. The tubes were mixed for 5 min 
and centrifuged (5 min, 1000 × g). The organic layer was evaporated 
to dryness at room temperature. The sample was reconstituted with 
200 µL acetonitrile and 800 µL water and transferred into a 1.5 mL vial 
(equal to a dilution factor 10).
LC-MS/MS
LC-MS/MS analysis was carried out using an UFLC Shimadzu 
system consisting of 2 LC-20ADXR pumps, a SIL-20ACXR 
autosampler, a DGU-20A3 degasser and a CTO-20A oven (Shimadzu 
Prominence, Antwerpen, Belgium) in combination with a 3200 
QTRAP (ABSciex, Halle, Belgium) and Analyst software (version 
1.5). An existing multi-target screening approach for this kind of 
apparatus was adapted from the literature: a scheduled multiple 
reaction monitoring-information dependent acquisition-enhanced 
product ion (sMRM-IDA-EPI) multi-target screening approach [4]. 
The method starts with a survey sMRM scan, where MRM transitions 
are only monitored during the expected retention time window. 
When a sMRM signal exceeds a preset IDA-threshold, an EPI scan is 
performed (this is a product scan where the third quadrupole is used 
as a linear ion trap). However, the original sMRM-IDA-EPI screening 
method is only performed in positive ionization and situations occur 
where compounds cannot be identified because the MRM signal is 
too low to trigger an EPI scan or because the EPI quality is insufficient 
for identification [4]. The existing method was optimized to overcome 
these shortcomings. The number of detected compounds was reduced 
from 700 to only 414 forensic relevant compounds (Table 1). An extra 
sMRM method in negative ionization mode measuring two MRM 
transitions for 38 compounds was added in order to detect a broader 
range of compounds (Table 2). However, the positive and negative 
method were not sensitive enough for detection of cannabis use, as 
shown by preliminary comparison of LC-MS/MS and immunoassays 
for some real-life forensic samples of cannabis users. To enhance the 
sensitivity of the screening for detection of cannabis, an important 
drug in forensic investigations, a MRM method for analysis of THC, 
THC-OH and THC-COOH was added (Table 2). In summary, each 
sample was injected three times and analyzed by three LC-MS/MS 
methods: (1) a sMRM-IDA-EPI method in positive ionization mode, 
(2) a sMRM method in negative mode and (3) a positive MRM 
method for detection of THC, THC-OH and THC-COOH.
LC conditions
The used pentafluorophenyl propyl column (5.0 µm particle 
size, 2.1 mm x 50 mm), fitted with a guard column (2.1 mm × 10 
mm, same packing material) and a filter of 2.0 µm, was purchased 
from Restek (via Interscience, Louvain-la-Neuve, Belgium). The 
autosampler temperature was set at 15°C, the column oven at 40°C. 
The autosampler needle was rinsed before and after sample injection 
to avoid carry over. The mobile phase consisted of water with 2 mM 
ammonium formate and 0.2% formic acid (A) and acetonitrile with 
2 mM ammonium formate and 0.2% formic acid (B). The positive 
sMRM-IDA-EPI and negative sMRM method had following gradient 
conditions: 0-10 min: 10-90%B and increase of flow rate from 0.5 mL/
min to 1 mL/min; 10-15 min: 90%B at 1 mL/min; 15-15.5 min: 90-
10%B; 15.5-17.5 min: 10%B at 0.5 mL/min. Following gradient at a 
flow rate of 0.5 mL/min was used in the MRM method: 0-10 min: 
10-90%B; 10-11 min: 90%B; 11-11.5 min: 90-10%B; 11.5-13.5 min: 
10%B. The injection volume was 30 µL.
MS/MS conditions
For all three LC-MS/MS experiments, electrospray conditions 
were as follows: gas 1: nitrogen, 40 psi; gas 2: nitrogen, 70 psi; ion-spray 
voltage: 4000 V (-4000 V in negative mode); ion-source temperature: 
500°C; curtain gas: nitrogen, 20 psi; collision gas: high. The 
declustering potential was 40 V (-40 V in negative mode), the entrance 
potential 10 V (-10 V in negative mode), the cell exit potential 5 V (-5 
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V in negative mode). Q1 and Q3 were operated in unit resolution. In 
the sMRM-IDA-API method, 414 MRM are measured ±90 s around 
the expected retention time of the compound (Table 1). The target 
scan time was 1 s with a pause between the sMRM transitions of 2 
ms. The used sMRM transitions were adapted from literature [4]. If 
the sMRM peak height exceeded the IDA-treshold (1000 counts per 
second (cps)) an EPI scan was triggered for the two most abundant 
sMRM signals. sMRM transitions which triggered the EPI scan twice 
consecutively were excluded for EPI scans for 15 s. The EPI scans were 
performed in a mass range from 50 to 640 Da at 4000 Da/s applying 
a collision energy (CE) of 35 ± 15 V, a fixed fill time of 50 ms and Q0 
trapping. The acquired EPI spectra were automatically compared to 
the used ABSciex MS/MS library containing 1253 compounds [7]. In 
negative ionization mode, a sMRM method was used containing 2 
sMRM transitions for each of 38 compounds (Table 2). Each MRM is 
measured ± 90 s around the expected retention time of the compound. 
For analysis of THC, THC-OH and THC-COOH a separate MRM 
method with dwell times of 30 ms was used (Table 2).
LC-MS/MS data analysis
For the sMRM-IDA-EPI method, a report was automatically 
generated. However, for accurate identification, manual review of the 
data is necessary [5]. Following criteria were used for identification: 
(1) the blank must be negative, (2) the IS must be present at the correct 
retention time with purity >75% and (3) the 4 (3 if ≤5 ions in the 
library spectrum) most abundant ions in the library spectrum must 
be present in the unknown spectrum. Ions present in the unknown 
spectrum that are not present in the library spectrum must be smaller 
than the 2 (3 if ≤5 ions in the library spectrum) most abundant ions 
in the unknown spectrum. For the (s)MRM methods, retention time, 
presence of the MRM transitions and ratio between MRM transitions 
were used for identification. 
Method validation
The process efficiency (PE%) that includes the influence of 
possible matrix effects (ME%) and recovery (RE%) was calculated. 
Two sets of samples were prepared for determination of PE%. In 
set 1, blank matrices (5 different sources of both urine and whole 
blood) were spiked with pure standard before sample preparation. 
Set 2 consisted of pure standards. Fifteen compounds with varying 
characteristics representing the broad range of compounds detected 
in this screening were carefully selected. Following formula was used 
to calculate the PE%:
ME% × RE% APE% = = ×100%
100 B
Where A is de peak area of the measured MRM transition from 
set 1, B from set 2. A value of 100% reflects the perfect situation. 
Clear guidelines on the acceptability of PE% values do not exist, so we 
had a look at the acceptance criteria for ME% and RE%. Acceptance 
criteria for ME% are set to 75-125% with a coefficient of variation 
Figure 1: PE% of the different sample preparations tested for ten compounds in urine (U) and whole blood (B).
Tested methods included: precipitation with acetonitrile and 10-fold dilution (1A), precipitation with acetone and 10-fold dilution (1B), protein precipitation with 
acetonitrile, 10-fold dilution and 0.2 µm filtration (2A°), protein precipitation with acetonitrile, 10-fold dilution and 0.45 µm filtration (2A*), protein precipitation 
with acetone, 10-fold dilution and 0.2 µm filtration (2B°), protein precipitation with acetone, 10-fold dilution and 0.45 µm filtration (2B*) and LLE using the 
Toxitubes (equal to a dilution factor 10) (3). The average and standard deviation of 10 measurements (5 different sources of both urine and whole blood, 
analyzed in duplicate) are shown. The numbers of the sample preparations that are significantly different are noted above each sample preparation (one-way 
ANOVA, Tukey-Kramer test, p<0.05). Tested concentrations in urine and whole blood were 2.5 µg/mL amphetamine, 0.75 µg/mL benzoylecgonine, 1.5 µg/
mL codeine, 0.375 µg/mL dextropropoxyphene, 2.5 µg/mL methamphetamine, 0.5 µg/mL methadone, 0.9 µg/mL methaqualone, 0.15 µg/mL morphine, 0.5 
µg/mL oxazepam and 0.125 µg/mL phencyclidine.
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Analytes in positive sMRM-IDA-EPI
17-Alpha-methyltestosterone Clomipramine Lisinopril Pilocarpine
2-Amino-5-chlorobenzophenone Clonazepam Loperamide Pindolol
2-Amino-5-nitrobenzophenone Clonidine Loratadine Pioglitazone
2-Hydroxyethylflurazepam Clopenthixol Lorazepam Pipamperone
3,4-Methylenedioxyamphetamine Clopidogrel Lormetazepam Pirbuterol
3,4-Methylenedioxyethylamphetamine Clozapine Losartan Pirenzepine
3,4-Methylenedioxymethamphetamine Cocaine Lysergide (LSD) Piritramide
6-O-Monoacetylmorphine Codeine Maprotiline Piroxicam
7-Aminoclonazepam Coniine MBDB Prajmalium
7-Aminodesmethylflunitrazepam Corticosterone Mebeverine Pramipexole
7-Aminoflunitrazepam Cortisone Meclizine Prazepam
7-Aminonitrazepam Cotinine Medazepam Prazosin
9-Hydroxyrisperidone Coumatetralyl Melatonin Prednisolone
Acebutolol Cyclicine Melitracen Prednisone
Aceclidine Cytarabine Meloxicam Primidone
Aceclofenac Desalkylflurazepam Melperone Procainamide
Aceprometazine Desipramine Mepindolol Procyclidine
Aciclovir Desmethylclobazam Mescaline Progesterone
Ajmaline Desmethylclomipramine Mesoridazine Promazine (IS)
Alizapride Dexamethasone Metaclazepam Promethazine
Allopurinol Dexamethasone 21-isonicotinate Metamfepramone Prometryn
Alpha-hydroxyalprazolam Dextromethorphan Methamphetamine Propafenone
Alpha-hydroxytriazolam Dextropropoxyphene Metformin Propionylpromazine
Alprazolam Diazepam Methadone Propranolol
Alprenolol Diclofenac Methaqualone Propyphenazone
Amantadine Diflucortolone Methotrexate Prothipendyl
Ambroxol Dihydrocodeine Methylephedrine Protriptyline
Amiloride Dihydroergotamine Methylphenidate Pseudoephedrine
Aminodantrolene Dilazep Metoprolol Psilocin
Aminophenazone Diltiazem Metronidazole Quetiapine
Aminopromazine Dimetotiazine Mexiletine Quinapril
Amiodarone Diphenhydramine Mianserin Quinine
Amiphenazole Dipyridamole Miconazole Ramipril
Amisulpride Disopyramide Midazolam Ranitidine
Amitriptyline Dixyrazine Midodrine Reboxetine
Amlodipine Dobutamine Milrinone Repaglinide
Amoxicillin Doxapram Minoxidil Reserpine
Amphetamine Doxepin Mirtazapine Risperidone
Apomorphine Doxylamine Mizolastine Ritodrine
Aprindine Ecgoninemethylester Moclobemide Ropinirole
Atenolol EDDP Modafinil Ropivacaine
Atorvastatin Embutramide Molsidomine Rosiglitazone
Atropine Enalapril Morphine Salbutamol
Atropinemethylbromide Ephedrine Morphine 3-β-D-glucuronide Scopolamine
Aztreonam Eprosartan Moxonidine Serotonin
Baclofen Esmolol Nalorphine Sertindole
Beclomethasone dipropionate Estazolam Naloxone Sertraline
Befunolol Ethenzamide Naltrexone Sildenafil
Bendiocarb Etomidate Nandrolone Simazine
Benperidol Etoposide Naphazoline Sotalol
Benzatropine Felbamate Nebivolol Stanozolol
Benzocaine Felodipine Nicardipine Sulfamethoxazole
Benzoctamine Fenarimol Nicotinamide Sulindac
Benzoylecgonine Fendiline Nicotine Sulpiride
Berberine Fenethylline Nifedipine Sumatriptan
Betamethasone 21-phosphate Fenfluramine Nifenazone Tadalafil
Betaxolol Fentanyl Nimodipine Talinolol
Bezafibrate Fexofenadine Nisoldipine Tamoxifen
Table 1: Analytes measured in the positive sMRM-IDA-EPI method. 
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(CV%= standard deviation divided by average) of maximum 15% 
(or 20% near the limit of detection) [8]. RE% is acceptable if the 
CV% is smaller than 15% (or 20% near the limit of detection) [8]. 
However, for qualitative methods acceptance criteria could be less 
strict. Selectivity was evaluated with blank samples from different 
sources (n=10 each for both urine and blood, no IS was added during 
sample preparation) and zero samples (n=2, IS was added to blank 
samples during sample preparation). To determine carryover, 30 µL 
H2O was injected as blank after every sample. Finally, 162 forensic 
urine and 146 whole blood samples were analyzed using the LC-MS/
MS method and compared with results from immunoassays and 
confirmation analyses, describing the accuracy, selectivity, sensitivity 
and carryover of the sample preparation and LC-MS/MS method.
With each batch, a quality control sample (blood or urine spiked with 
CON-DOA) was run to check overall system performance. 
Results and Discussion
Seven sample preparations (resulting in a 10-fold dilution of the 
urine and blood samples) were tested for ten compounds with varying 
characteristics representing the broad spectrum of compounds that 
can be found in forensic samples (amphetamine, benzoylecgonine, 
codeine, dextropropoxyphene, methamphetamine, methadone, 
methaqualone, morphine, oxazepam and phencyclidine) (Figure 1). 
Precipitation, aqueous dilution and filtration had an equal or lower 
Biperiden Flecainide Nitrazepam Telmisartan
Bisoprolol Fluconazole Nitrendipine Temazepam
Brodifacoum Flumazenil Norbuprenorphine Tenoxicam
Bromazepam Flunarizine Nordiazepam Terbinafine
Bromocriptine Flunitrazepam Norephedrine Terbutaline
Brompheniramine Fluoxetine Norfenefrine Terfenadine
Brotizolam Flupentixol Norfentanyl Tetracaine
Bucetin Fluphenazine Norfloxacin Tetrazepam
Bumetanide Flurazepam Normorphine Tetryzoline
Bunitrolol Fluvoxamine Nortriptyline Thebacon
Bupivacaine Gabapentin Noscapine Theobromine
Bupranolol Galantamine Ofloxacin Theophylline
Buprenorphine Gallopamil Olanzapine Thiamine
Buspirone Gemcitabine Ondansetron Thioridazine
Butaperazine Glibenclamide Opipramol Tiagabine
Caffeine Glibornuride Ornidazole Tiapride
Candesartan Gliclazide Orphenadrine Ticlopidine
Captopril Glimepiride Oxazepam Tilidine
Carazolol Glipizide Oxcarbazepine Timolol
Carbamazepine Gliquidone Oxetacaine Tizanidine
Carbamazepine 10,11-epoxide Guaifenesin Oxilofrine Tocainide
Carbinoxamine Haloperidol Oxitropium Tolbutamide
Carbuterol Heroin Oxprenolol Toliprolol
Carteolol Hydrocodone Oxycodone Tramadol
Carvedilol Hydrocortisone Oxymorphone Tranexamic acid
Celiprolol Hydrocortisone 21- acetate Papaverine Trazodone
Cetirizine Hydromorphone Paracetamol Triamterene
Chlorcyclizine Hydroxyzine Paraoxon Triazolam
Chlordiazepoxide Imipramine Paroxetine Trifluperazine
Chlorphenethiazine Indinavir Pentamidine Trifluperidol
Chlorpheniramine Indapamide Pentoxyverine Triflupromazine
Chlorpromazine Indometacin Perazine Trimethoprim
Chlorpromazine sulfoxide Indoprofen Perindopril Trimipramine
Chlorprothixene Ipratropium Perphenazine Urapidil
Cilazapril Irbesartan Phenelzine Valsartan
Cinnarizine Isoprenaline Pheniramine Vardenafil
Ciprofloxacin Kavain Phenprocoumon Venlafaxine
Cisapride Ketamine Phenylephrine Verapamil
Citalopram Ketoprofen Phenyltoloxamine Vincamine
Clarithromycin Ketorolac Phenytoin Warfarin
Clemastine Lamotrigine Pholedrine Xylometazoline
Clenbuterol Lercanidipine Pethidine (Meperidine) Yohimbine
Clobazam Levocabastine Phenacetin Zolpidem
Clobenzepam Levodopa Phenazone Zopiclone
Clobutinol Levomepromazine Phencyclidine Zuclopenthixol
Clomethiazole Lidocaine Physostigmine
Compound dependent parameters and retention times were adapted from literature [4].
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PE% than the same procedure without filtration (Figure 1(2 versus 
1)). The LLE using the Toxitubes was highly variable and showed a low 
PE% for most of the compounds (Figure 1(3)). Samples treated with 
acetonitrile had in general less variability than samples treated with 
acetone (Figure 1(A versus B)). There was no significant difference 
between filtration membranes of 0.45 µm and 0.2 µm (Figure 1(* 
versus °)). Based on the following three criteria (i.e. PE% around 
100%, low variability and ease of use), protein precipitation with 
acetonitrile and aqueous dilution was selected as the optimal sample 
preparation (Figure 1(1A)).
Since urine samples are in general cleaner and have a lower 
viscosity than whole blood samples, we tried to lower the dilution 
factor in order to enhance sensitivity. We tested undiluted urine, 
dilution factor 5 and 10 for the screening of spiked urine samples (see 
values for “urine, high”, Table 3). As expected, significant and highly 
variable matrix effects were seen when directly injecting urine after 
centrifugation. Moreover, a shift in retention time from run to run 
was seen as a consequence of contamination of the LC column. Five- 
and 10-fold dilution had better PE% values and lower variability. 
As a compromise between sensitivity and repeatability, protein 
precipitation with acetonitrile and 5-fold dilution was selected as the 
sample preparation for urine. 
The PE% of the selected sample preparations (i.e. protein 
precipitation with acetonitrile and 5-fold dilution for urine and 
protein precipitation with acetonitrile and 10-fold dilution for blood) 
was further measured in both matrices for the ten compounds at 
different concentration levels, to ensure its analytical quality at 
different concentrations and in blood for five substances almost 100% 
Analyte (RT in min shown for sMRM) Q1 (m/z) Q2 (m/z) CE (V)
2-Amino-5-nitrobenzophenone (4.3) 241.1 134.1/163.1 -35/-20
4-Benzamidosalicyclic acid (3.2) 256.1 212.1/134.0 -20/-35
5-Aminosalicylic acid (0.1) 152.0 108.0/107.0 -20/-35
5-(p-Methylphenyl)-phenylhydantoin 
(3.2) 265.1 116.0/102.0 -35/-35
6-Mercaptopurine (0.1) 151.0 92.0/90.0 -35/-50
Acetazolamide (0.5) 221.0 83.0/79.9 -35/-35
Acetylsalicylic acid (1.7) 179.0 93.0/137.0 -35/-20
Adenine (0.1) 134.1 107.0/92.0 -20/-35
Adenosine (0.1) 266.1 134.1/107.0 -50/-50
Adrenalone (0.1) 180.1 108.0/147.1 -35/-20
Alprostadil (3.1) 353.2 113.0/317.2 -50/-50
Amobarbital (2.6) 225.1 136.2/182.2 -35/-20
Amoxicillin (0.7) 364.1 206.1/93.0 -20/-35
Atorvastatin (4.4) 557.3 278.2/397.52 -50/-35
Aztreonam (0.1) 434.1 95.9/79.9 -50/-50
Barbital (0.0) 183.1 140.1/84.9 -20/-20
Benserazide (0.1) 256.1 137.0/109.0 -20/-35
Benzthiazide (3.3) 430.0 308.1/228.1 -35/-50
Bezafibrate (3.8) 360.1 274.2/154.1 -20/-35
Brallobarbital (2.9) 285.0 78.8/205.1 -20/-20
Butalbital (0.0) 223.1 180.2/94.1 -50/-20
Butallylonal (0.0) 301.0 78.9/221.2 -20/-35
Carbenoxolone (5.2) 569.4 469.3/99.0 -50/-50
Chlorothiazide (0.9) 293.9 214.0/179.1 -35/-50
Cimetidine (0.9) 251.1 97.0/123.1 -35/-20
Cortisone (2.5) 359.2 329.3/137.1 -20/-50
Dinoprost (3.1) 353.2 83.0/165.2 -35/-35
Epinephrine (0.1) 182.1 164.1/122.0 -20/-35
Ethylglucuronide (0.1) 221.1 84.9/74.9 -22/-22
Ethylsulfate (0.1) 125.0 96.8/79.8 -22/-42
Furosemide (2.9) 329.0 285.1/205.1 -20/-35
Hydrochlorothiazide (1.0) 296.0 205.1/77.9 -35/-50
Pentobarbital (2.6) 225.1 182.2/138.2 -20/-20
Phenobarbital (1.9) 231.1 188.2/144.1 -20/-20
Propallylonal (2.9) 287.0 78.8/207.1 -35/-20
THC-COOH (5.1) 343.2 299.3/245.2 -35/-36
THC-OH (5.5) 329.1 311.0/268.0 -27/-33
Triamcinolone (1.9) 393.2 345.3/325.3 -20/-20
THC 315.2 193.2/259.2/123.1 35/20/35
THC-OH 331.2 313.2/193.2/201.2 20/35/35 
THC-COOH 345.2 327.2/299.2/193.2 20/20/35
A RT of 0.0 indicates that the MRM transitions are measured during the entire run (for compounds with an unknown RT)
Table 2: Analytes, their retention time (RT) and MRM parameters (Q1, Q2 and collision energy (CE)) measured in the negative sMRM method for detection of 38 
compounds and the positive MRM method for detection of THC and metabolites.
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bound to plasma proteins (see values in italic, Table 3). These five 
(buprenorphine, clomipramine, cocaine, midazolam and zolpidem) 
were included to ensure that the used sample preparation works for 
all compounds. The lowest PE% can be expected in blood, where the 
protein precipitation is more drastic than in urine. Drugs that are 
highly bound to proteins in the blood have an increased risk of being 
lost in the precipitant. Therefore, their behavior was tested. All PE% 
values were higher than 60% with CV% smaller than 30%, except for 
morphine in urine (see values in italic, Table 3). The obtained PE% 
Precipitation and 10-fold dilution Precipitation and 5-fold dilution Direct injection
Analyte (Fb)
Blood, low Blood, high Urine, high Urine, low Urine, high Urine, high
PE% CV% PE% CV% PE% CV% PE% CV% PE% CV% PE% CV%
Amphetamine (0.16) 95 3 91 8 86 8 91 19 78 16 48 41
Benzoylecgonine (?) 87 8 82 5 85 15 69 21 79 20 32 64
Buprenorphine (0.96) 103 27 105 15 - - - - - - - -
Clomipramine (0.96) 88 7 90 6 - - - - - - - -
Cocaine (0.92) 115 7 113 2 - - - - - - - -
Codeine (0.07-0.25) 104 6 96 11 97 13 66 27 75 15 30 46
Dextropropoxyphene (0.78) 89 12 95 5 90 9 101 7 100 11 114 34
Methamphetamine (?) 96 5 91 5 87 4 59 21 74 14 33 53
Methadone (0.87) 82 7 79 4 89 9 90 10 91 12 176 34
Methaqualone (0.80) 91 5 104 9 80 15 79 12 81 21 44 53
Midazolam (0.96) 93 8 88 6 - - - - - - - -
Morphine (0.35) 104 14 100 17 74 18 56 44 60 27 19 66
Oxazepam (0.87-0.94) 78 8 79 6 74 11 82 15 64 25 42 45
Phencyclidine (0.65) 69 10 87 8 89 6 101 6 96 5 96 26
Zolpidem (0.93) 91 11 74 30 - - - - - - - -
Tested methods included: protein precipitation with acetonitrile and dilution with water (resulting in a dilution factor 5 or 10) and direct injection (after centrifugation). 
The average PE% and CV% of 10 measurements (5 different sources of both urine and whole blood, analyzed in duplicate) are shown. Tested concentrations were 
0.3 and 2.5 µg/mL amphetamine, 0.09 and 0.75 µg/mL benzoylecgonine, 0.1 and 1 µg/mL buprenorphine, 0.18 and 1.5 µg/mL codeine, 0.1 and 1 µg/mL clomipramine, 
0.1 and 1 µg/mL cocaine, 0.05 and 0.375 µg/mL dextropropoxyphene, 0.3 and 2.5 µg/mL methamphetamine, 0.15 and 0.5 µg/mL methadone, 0.1 and 0.9 µg/mL 
methaqualone, 0.1 and 1 µg/mL midazolam, 0.06 and 0.150 µg/mL morphine, 0.05 and 0.5 µg/mL oxazepam, 0.015 and 0.125 µg/mL phencyclidine and 0.1 and 1 µg/
mL zolpidem in urine and blood, low and high concentrations respectively. The values in italic show the PE% and CV% of the selected optimal sample preparation.
Table 3: Fraction bound to plasma protein (Fb), PE% and CV% for 15 compounds in urine and blood analyzed with the LC-MS/MS screening.
values were considered acceptable for screening. The method was 
found to be selective. No carryover was seen.
Finally, the optimized sample preparation and three LC-MS/MS 
methodswere used for screening of 162 forensic urine samples and 
146 whole blood samples (both ante- and post-mortem species). These 
samples were also analyzed with the appropriate immunoassay and 
confirmation techniques routinely used in the laboratory (Table 4). To 
evaluate LC-MS/MS as an alternative tool to immunoassay screening, 
the number of true and false positive and negative results obtained 
Urine samples AXSYM® immunoassay LC-MS/MS screening Confirmation
 False + False - True + True - False + False - True + True - +  -
Amphetamine/methamphetamine 6 1 14 141 1 1 14 146 15 147
Barbiturates 2 0 2 158 0 0 2 160 2 160
Benzodiazepines 2 24 52 84 0 8 65 86 76 86
Cannabinoids 2 4 21 135 0 1 24 137 25 137
Cocaine 1 12 12 137 0 5 19 138 24 138
Methadone 21 1 13 127 0 2 12 148 14 148
Opiates 1 13 13 135 1 4 22 135 26 136
Tricyclic antidepressants 9 0 3 150 0 0 3 159 3 159
TOTAL 44 55 130 1067 2 21 164 1109 185 1111
Blood samples Cozart® immunoassay LC-MS/MS screening  Confirmation
 False + False - True + True - False + False - True + True - + -
Amphetamine/methamphetamine 4 6 3 133 1 1 8 136 9 136
Barbiturates 0 0 1 145 0 0 1 145 1 145
Benzodiazepines 0 32 24 90 0 11 45 90 56 90
Cannabinoids 0 5 16 125 0 2 19 125 21 125
Cocaine 0 12 5 129 0 4 13 129 17 129
Methadone 0 0 3 143 0 0 3 143 3 143
Opiates 0 12 8 126 0 5 15 126 20 126
Total 4 67 60 891 1 23 104 894 127 895
The number of total positive (+) and negative (-) samples was derived from the information obtained with confirmation techniques (GC-MS, LC-DAD, LC-MS/MS). 75% 
of the analyzed urine samples and 57% of the blood samples were post-mortem. 47 of 162 urine samples and 63 of 146 blood samples were negative for all compound 
classes analyzed by the immunoassays.
Table 4: Real-life forensic urine and blood samples screened with immunoassays and LC-MS/MS. 
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by both techniques was compared. For urine samples, screening 
by immunoassay resulted in a higher number of false positives (44 
versus 2) and false negatives (55 versus 21) than screening by LC-
MS/MS (Table 4). For blood samples, the immunoassay also had a 
higher number of false negatives (67 versus 23) and false positives (4 
versus 1) (Table 4). The Cozart® immunoassay had a lower number 
of false positives than the Axsym® system, as the Cozart® tests 
include less compounds in each class. The higher number of false 
positives for urine samples analyzed by the immunoassay can be 
explained by the low selectivity of the immunoassay: there is cross-
reactivity with molecules structurally related to the target analyte(s) 
(e.g. in post-mortem samples, amphetamine-like compounds can 
be present because of putrefaction, generating a false positive result 
in the immunoassay). The higher number of false positives results 
in a higher cost (since more confirmation tests are required). False 
negative results were seen for samples containing low levels of drugs 
or if a compound is just not detected by the immunoassay (e.g. the 
Cozart® test for opiates does not react with fentanyl or tramadol 
which are detected by LC-MS/MS). Evidently, false negatives should 
be avoided in forensic toxicology. Considering the number of true 
and false results, LC-MS/MS screening was more specific, sensitive 
and correct than the immunoassay. The saving of time of screening 
by LC-MS/MS compared to the immunoassays was limited because 
of the need to analyze each sample with three different LC-MS/MS 
methods. However, because of the gain in efficiency, analysis time was 
considered of secondary importance. 
Conclusions
In the search for an alternative for screening by immunoassays, 
several sample preparations of urine and whole blood followed by 
LC-MS/MS analysis were evaluated. Protein precipitation using 
acetonitrile combined with aqueous dilution (dilution factor 5 for 
urine and 10 for blood) proved to be an effective sample preparation 
for screening using LC-MS/MS. The samples were analyzed by three 
LC-MS/MS methods (sMRM-IDA-EPI for 414 positively charged 
compounds, negative sMRM for 38 acidic compounds and positive 
MRM method for THC and two metabolites) in order to cover a broad 
range of forensic relevant compounds. To the best of our knowledge 
this is the first LC-MS/MS method for screening of both ante- and 
post-mortem urine and whole blood. For 162 forensic urine samples 
and 146 whole blood samples, screening by LC-MS/MS performed 
superiorly compared to the immunoassays. Hence, LC-MS/MS can be 
considered a trustworthy alternative to immunoassays for screening 
in forensic toxicology. 
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